FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 79 filers reported holding FATE THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,064,941 | -54.4% | 2,389,123 | +2.3% | 0.03% | -53.1% |
| Q2 2023 | $11,115,162 | +45.1% | 2,335,118 | +73.8% | 0.06% | +36.2% |
| Q1 2023 | $7,658,685 | +11682.6% | 1,343,629 | +8143.1% | 0.05% | +4600.0% |
| Q3 2017 | $65,000 | -59.9% | 16,300 | -67.4% | 0.00% | -66.7% |
| Q2 2017 | $162,000 | -41.3% | 50,004 | -17.6% | 0.00% | -50.0% |
| Q1 2017 | $276,000 | +16.9% | 60,704 | -35.4% | 0.01% | +20.0% |
| Q4 2016 | $236,000 | -39.2% | 93,982 | -24.5% | 0.01% | -28.6% |
| Q3 2016 | $388,000 | +27.6% | 124,472 | -30.3% | 0.01% | +16.7% |
| Q2 2016 | $304,000 | -17.4% | 178,647 | -12.6% | 0.01% | -25.0% |
| Q1 2016 | $368,000 | +192.1% | 204,447 | +448.8% | 0.01% | +166.7% |
| Q4 2015 | $126,000 | – | 37,253 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |